These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7946573)

  • 1. Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group.
    Abad A; Masuti B; Camps C; Font A; Balañá C; Vicent JM; Sánchez JJ
    Eur J Cancer; 1994; 30A(7):1043. PubMed ID: 7946573
    [No Abstract]   [Full Text] [Related]  

  • 2. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group.
    Wils J; Bleiberg H; Buyse M; Wagener DT; Splinter T; Veenhof C; Herben M; Duez N
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1119-20. PubMed ID: 2759166
    [No Abstract]   [Full Text] [Related]  

  • 3. Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma.
    Di Bartolomeo M; Zampino MG; Di Leo A; Bajetta E
    Eur J Cancer; 1993; 29A(8):1215-6. PubMed ID: 8518036
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Kornek G; Raderer M; Schenk T; Pidlich J; Schulz F; Globits S; Tetzner C; Scheithauer W
    Cancer; 1995 Oct; 76(8):1356-62. PubMed ID: 8620409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas.
    Topham C; Glees J; Coombes RC
    Oncology; 1993 Apr; 50 Suppl 1():78-80. PubMed ID: 8483561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
    Evans TR; Lofts FJ; Mansi JL; Glees JP; Dalgleish AG; Knight MJ
    Br J Cancer; 1996 May; 73(10):1260-4. PubMed ID: 8630289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma.
    Raymond E; de Gramont A; Louvet C; Tournigand C; Demuynck B; Beerblock K; Carola E; Krulik M
    Eur J Cancer; 1997 Apr; 33(4):696-7. PubMed ID: 9274458
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study.
    Louvet C; Beerblock K; de Gramont A; Varette C; Demuynck B; Bennamoun M; Cady J; Delfau S; Maisani JE; Krulik M
    Eur J Cancer; 1993; 29A(8):1217. PubMed ID: 8518038
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.
    Miller RL; Bukowski RM; Budd GT; Purvis J; Weick JK; Shepard K; Midha KK; Ganapathi R
    J Clin Oncol; 1988 May; 6(5):880-8. PubMed ID: 3367191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.
    Loehrer PJ; Williams SD; Nichols CR
    Cancer Treat Rep; 1987 Nov; 71(11):1115-6. PubMed ID: 3119208
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
    Topham C; Glees J; Rawson NS; Woods EM; Coombes RC
    Br J Cancer; 1991 Jul; 64(1):179-81. PubMed ID: 1906726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
    Sun W; Metz JM; Gallagher M; O'Dwyer PJ; Giantonio B; Whittington R; Haller DG
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):621-7. PubMed ID: 20495918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
    Mambrini A; Bassi C; Pacetti P; Torri T; Iacono C; Ballardini M; Orlandi M; Guadagni S; Fiorentini G; Cantore M
    Pancreas; 2008 Jan; 36(1):56-60. PubMed ID: 18192882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
    Kobayashi A; Yamaguchi M
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1755-9. PubMed ID: 9757202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.
    Sun W; Whittington R; Gallagher M; O'Dwyer P; Giantonio B; Metz J; Haller D
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):39-42. PubMed ID: 15685833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy].
    Minari Y; Nio Y; Endo S; Yano S; Itakura M; Yamasawa K; Tamura K
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):121-5. PubMed ID: 10660744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.
    Milandri C; Calzolari F; Passardi A; Tison C; Giampalma E; Cecconetto L; Golfieri R
    Hepatogastroenterology; 2007 Dec; 54(80):2373-7. PubMed ID: 18265668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer.
    Okines AF; Asghar U; Cunningham D; Ashley S; Ashton J; Jackson K; Hawkes E; Chau I
    Oncology; 2010; 79(1-2):150-8. PubMed ID: 21150230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of epirubicin in patients with advanced adenocarcinoma of the pancreas.
    Aoki K; Shimada Y; Okazaki N; Tajiri H; Nose H; Okada S; Shirao K; Yokota T; Yoshida S; Saitoh D
    Eur J Cancer; 1992; 28A(8-9):1590. PubMed ID: 1515280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.